Advanced search
Publication Cover
Drug Metabolism Reviews Volume 48, 2016 - Issue 2
Submit an article Journal homepage
5,142
Views
14
CrossRef citations to date
0
Altmetric
Review Article

Biotransformation and bioactivation reactions – 2015 literature highlights

Thomas A. BaillieSchool of Pharmacy, University of Washington, Seattle, WA, USA;
,
Deepak DalviePfizer Global Research and Development, La Jolla Laboratories, San Diego, CA, USA;
,
Ivonne M. C. M. RietjensDivision of Toxicology, Wageningen University, Wageningen, The Netherlands;
&
S. Cyrus KhojastehDepartment of Drug Metabolism and Pharmacokinetics, Genentech, 1 DNA Way, South San Francisco, CA, USACorrespondence[email protected]
Pages 113-138 | Received 29 Apr 2016, Accepted 25 May 2016, Published online: 30 Jun 2016

References

  • Akhtar M, Wright JN, Lee-Robichaud P. (2011). A review of mechanistic studies on aromatase (CYP19) and 17alpha-hydroxylase-17,20-lyase (CYP17). J Steroid Biochem Mol Biol 125:2–12.
  • den Besten C, van Bladeren PJ, Duizer E, et al. (1993). Cytochrome P450-mediated oxidation of pentafluorophenol to tetrafluorobenzoquinone as the primary reaction product. Chem Res Toxicol 6:674–680.
  • Kitagawara Y, Ohe T, Tachibana K, et al. (2015). Novel bioactivation pathway of benzbromarone mediated by cytochrome P450. Drug Metab Dispos 43:1303–1306.
  • Kobayashi K, Kajiwara E, Ishikawa M, et al. (2012). Identification ofisozymes involved in benzbromarone metabolism in human liver microsomes. Biopharm Drug Dispos 33:466–473.
  • Li JJ, Purdy RH, Appelman EH, et al. (1985). Catechol formation of fluoro- and bromo-substituted estradiols by hamster liver microsomes. Evidence for dehalogenation. Mol Pharmacol 27:559–565.
  • McDonald MG, Rettie AE. (2007). Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. Chem Res Toxicol 20:1833–1842.
  • Ohe T, Mashino T, Hirobe M. (1997). Substituent elimination from p-substituted phenols by cytochrome P450. ipso-substitution by the oxygen atom of the active species. Drug Metab Dispos 25:116–122.
  • Park BK, Kitteringham NR. (1994). Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications. Drug Metab Rev 26:605–643.
  • Rietjens CM, Vervoort J. (1992.) A new hypothesis for the mechanism for cytochrome P-450 dependent aerobic conversion of hexahalogenated benzenes to pentahalogenated phenols. Chem Res Toxicol 5:10–19. [https://doi.org/10.1021/tx00025a004]
  • Varfaj F, Zulkifli SN, Park HG, et al. (2014). Carbon–carbon bond cleavage in activation of the prodrug nabumetone. Drug Metab Dispos 42:828–838.
  • Vatsis KP, Coon MJ. (2002). Ipso-substitution by cytochrome P450 with conversion of p-hydroxybenzene derivatives to hydroquinone: Evidence for hydroperoxo-iron as the active oxygen species. Arch Biochem Biophys 397:119–129.

References

  • Gu C, Lewis RJ, Wells AS, et al. (2015). Lipid peroxide-mediated oxidative rearrangement of the pyrazinone carboxamide core of neutrophil elastase inhibitor AZD9819 in blood plasma samples. Drug Metab Dispos 43:1441–1449.
  • Guengerich FP. (2001a). Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611–650.
  • Guengerich FP. (2001b). Uncommon P450-catalyzed reactions. Cur Drug Metab 2:93–115.
  • Guengerich FP. (2007). Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J Biochem Mol Toxicol 21:163–168.
  • Singh R, Silva Elipe MV, Pearson PG, et al. (2003). Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins. Chem Res Toxicol 16:198–207.
  • Subramanian R, Lin CC, Ho JZ, et al. (2003) Bioactivation of the 3-amino-6-chloropyrazinone ring in a thrombin inhibitor leads to novel dihydro-imidazole and imidazolidine derivatives: structures and mechanism using 13C-labels, mass spectrometry, and NMR. Drug Metab Dispos 31:1437–1447.

References

  • Brandange S, Lindblom L. (1979). The enzyme “aldehyde oxidase” is an iminium oxidase. Reaction with nicotine delta 1'(5') iminium ion. Biochem Biophys Res Commun 91:991–996.
  • Fiorentini F, Geier M, Binda C, et al. (2016). Biocatalytic characterization of human FMO5: unearthing Baeyer–Villiger reactions in humans. ACS Chem Biol. 11:1039–48.
  • Lai WG, Farah N, Moniz GA, Wong YN. (2011). A Baeyer–Villiger oxidation specifically catalyzed by human flavin-containing monooxygenase 5. Drug Metab Dispos 39:61–70.
  • Meng J, Zhong D, Li L, et al. (2015). Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: The oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes. Drug Metab Dispos 43:646–659.
  • Murphy PJ. (1973). Enzymatic oxidation of nicotine to nicotine 1'(5') iminium ion. A newly discovered intermediate in the metabolism of nicotine. J Biol Chem 248:2796–2800.
  • Rousu T, Pelkonen O, Tolonen A. (2009) Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 23:843–855.
  • Wu E, Shinka T, Caldera-Munoz P, et al. (1988). Metabolic studies on the nigrostriatal toxin MPTP and its MAO B generated dihydropyridinium metabolite MPDP+. Chem Res Toxicol 1:186–194.
  • Xu S, Zhu B, Teffera Y, et al. (2005). Metabolic activation of fluoropyrrolidine dipeptidyl peptidase-IV inhibitors by rat liver microsomes. Drug Metab Dispos 33:121–130.
  • Zhang KE, Naue JA, Arison B, Vyas KP. (1996). Microsomal metabolism of the 5-lipoxygenase inhibitor L-739,010: Evidence for furan bioactivation. Chem Res Toxicol 9:547–554.

References

  • Hagiya Y, Kamata S, Mitsuoka S, et al. (2015). Hemizygosity of transsulfuration genes confers increased vulnerability against acetaminophen-induced hepatotoxicity in mice. Toxicol Appl Pharmacol 282:195–206.
  • Ida T, Sawa T, Ihara H, et al. (2014). Reactive cysteine persulfides and S-polythiolation regulate oxidative stress and redox signaling. Proc Natl Acad Sci USA 111:7606–7611.
  • Sun J, Schnackenberg LK, Holland RD, et al. (2008). Metabonomics evaluation of urine from rats given acute and chronic doses of acetaminophen using NMR and UPLC/MS. J. Chrom B: Anal Technol Biomed Life Sci 871:328–340.

References

  • Diamond S, Boer J, Maduskie TP, et al. (2010). Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277–1285.
  • Infante JR, Rugg T, Gordon M, et al. (2013). Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET. Invest New Drugs 31:363–369.
  • Moriwaki Y, Yamamoto T, Takahashi S, et al. (2001). Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining. Histol Histopathol 16:745–753.
  • Sanoh S, Tayama Y, Sugihara K, et al. (2015). Significance of aldehyde oxidase during drug development: Effects on drug metabolism, pharmacokinetics, toxicity, and efficacy. Drug Metab Pharmacokinet 30:52–63.
  • Smith DA, Obach RS. (2009). Metabolites in safety testing (MIST): Considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22:267–279.

References

  • Carmella SG, Akerkar S, Hecht, SS. (1993). Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers’ urine. Cancer Res 53:721–724.
  • Carmella SG, Akerkar SA, Richie Jr. JP, Hecht SS. (1995). Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers’ urine. Cancer Epidemiol Biomarkers Prev 4:635–642.
  • Carmella SG, Le K-A, Upadhyaya P, Hecht SS. (2002). Analysis of N- and O-glucuronides of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Chem Res Toxicol 15:545–550.
  • Hecht SS, Trushin N, Reid-Quinn CA, et al. (1993). Metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the patas monkey: Pharmacokinetics and characterization of glucuronide metabolites. Carcinogenesis 14:229–236.
  • Lao Y, Yu N, Kassie F, Villalta PW, Hecht SS. (2007). Formation and accumulation of pyridyloxobutyl DNA adducts in F344 rats chronically treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of its metabolite, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol 20:235–245.
  • Richter E, Engl J, Friesenegger S, Tricker AR. (2009). Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in lung tissue from mouse, rat, hamster, and man. Chem Res Toxicol 22:1008–1017.
  • Rietjens IMCM, Louisse J, Punt A. (2011). Tutorial on physiologically based kinetic (PBK) modelling in molecular nutrition and food research. Mol Nutr Food Res 55:941–956.
  • Upadhyaya P, Kenney PM, Hochalter JB, et al. (1999). Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouse. Carcinogenesis 20:1577–1582.
  • Zhang S, Wang M, Villalta PW, et al. (2009). Analysis of pyridyloxobutyl and pyridylhydroxybutyl DNA adducts in extrahepatic tissues of F344 rats treated chronically with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol 22:926–936.

References

  • Huang CH, Ren FR, Shan GQ, et al. (2015). Molecular mechanism of metal-independent decomposition of organic hydroperoxides by halogenated quinoid carcinogens and the potential biological implications. Chem Res Toxicol 28:831–837.
  • Qin F, Zhao YY, Zhao YL, et al. (2010) A toxic disinfection by-product, 2,6-dichloro-1,4-benzoquinone, identified in drinking water. Angew Chem Int Ed 49:790–792.
  • Zhao YL, Qin F, Boyd JM, et al. (2010) Characterization and determination of chloro- and bromo-benzoquinones as new chlorination disinfection byproducts in drinking water. Anal Chem 82:4599–4605.

References

  • Boberg EW, Miller EC, Miller JA, et al. (1983). Strong evidence from studies with Brachymorphic mice and pentachlorophenol that 1'-sulfooxysafrole is the major ultimate electrophilic and carcinogenic metabolite of 1'-hydroxysafrole in mouse liver. Cancer Res 43:5163–5173.
  • Borchert P, Miller JA, Miller EC, Shires TK. (1973). 1'-Hydroxysafrole a proximate carcinogenic metabolite of safrole in the rat and mouse. Cancer Res 33:590–600.
  • Cartus AT, Stegmüller S, Simson N, et al. (2015). Hepatic metabolism of carcinogenic β-asarone. Chem Res Toxicol 28:1760–1773.
  • COE (Committee of Experts on Flavouring Substances of the Council of Europe). (2005). The 1st report on active principles (Constituents of Toxicological Concern) contained in natural sources of flavourings. Available from: http://www.coe.int/t/e/social_cohesion/soc%2Dsp/public_health/flavouring_substances/Active%20principles.pdf.
  • Drinkwater NR, Miller EC, Miller JA, Pitot HC. (1976). Hepatocarcinogenicity of estragole (1-allyl-4-methoxybenzene) and 1’-hydroxyestragole in the mouse and mutagenicity of 1'-acetoxyestragole in bacteria. J Natl Cancer Inst 57:1323–1331.
  • Rietjens IMCM, Adams TB, Bastaki M, et al. (2014). The impact of structural and metabolic variation on the toxicity and carcinogenicity of hydroxy- and alkoxy-substituted allyl- and propenylbenzenes. Chem Res Toxicol 27:1092–1103.
  • SCF (Scientific Committee on Food). (2002). Opinion of the Scientific Committee on food on the presence of β-asarone in flavourings and other food ingredients with flavouring properties, SCF/CS/FLAV/FLAVOUR/9 ADD1 Final. Available from: http://ec.europa.eu/food/fs/sc/scf/out111_en.pdf.
  • Truhaut R, Le Bourhis B, Attia M, et al. (1989) Chronic toxicity/carcinogenicity study of trans-anethole in rats. Fd Chem Toxico 27:11704–11720.
  • Wiseman RW, Fennell TR, Miller JA, Miller EC. (1985). Further characterization of the DNA adducts formed by electrophilic esters of the hepatocarcinogens 1'-hydroxysafrole and 1'-hydroxyestragole in vitro and in mouse liver in vivo, including new adducts at C-8 and N-7 of guanine residues. Cancer Res 45:3096–3105.
  • Wiseman RW, Miller EC, Miller JA, Liem A. (1987). Structure-activity studies of the hepatocarcinogenicities of alkenylbenzene derivatives related to estragole and safrole on administration to preweanling male C57BL/6J × C3H/HeJ F1 mice. Cancer Res 47:2275–2278.
  • Wislocki PG, Borchert P, Miller JA, Miller EC. (1976). The metabolic activation of the carcinogen 1'-hydroxysafrole in vivo and in vitro and the electrophilic reactivities of possible ultimate carcinogens. Cancer Res 36:1686–1695.
  • Wislocki PG, Miller EC, Miller JA, et al. (1977) Carcinogenic and mutagenic activities of safrole, 1'-hydroxysafrole, and some known or possible metabolites. Cancer Res 37:1883–1891.

References

Reference

  • Wabnitz PA, Mitchell D, Wabnitz DA. (2004). In Vitro and in vivo metabolism of the anti-cancer agent CI-1040, a MEK inhibitor, in rat, monkey, and human. Pharm Res 21:1670–1679.

References

  • Barr JT, Choughule K, Jones JP. (2014). Enzyme kinetics, inhibition, and regioselectivity of aldehyde oxidase. Methods Mol Biol 1113:167–186.
  • Garattini E, Terao M. (2013). Aldehyde oxidase and its importance in novel drug discovery: present and future challenges. Expert Opin Drug Discov 8:641–654.
  • Gordon AH, Green DE, Subrahmanyan V. (1940). Liver aldehyde oxidase. Biochem J 34:764–74.
  • Sanoh S, Tayama Y, Sugihara K, et al. (2015). Significance of aldehyde oxidase during drug development: Effects on drug metabolism, pharmacokinetics, toxicity, and efficacy. Drug Metab Pharmacokinet 30:52–63.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.